Table 3 Lung cancer genomic sequencing classifier validation performance (Down, up classification). *Cancer prevalence calculation includes local benign subjects as Prevalence = \( \frac{\# Malignant}{\# Malignant+\# Benign+\# Local\ Benign} \). The local benign subjects had local label as benign but did not have an adjudicated label. NPV, PPV and % Reclassified are all functions of prevalence (estimated including local benign subjects), sensitivity and specificity (both estimated excluding local benign subjects)
AUC | Pre-test Cancer Risk | *Cancer prevalence | Cancer risk re-stratification | Specificity | Sensitivity | Post-test NPV/PPV | §% Re-stratified |
|---|---|---|---|---|---|---|---|
73.4% [68.3–78.4] | Low | 5% | Low to Very Low | 57.4% [44.8–69.3] | 100% [39.8–100] | 100% NPV [91.0–100] | 54.5% |
Intermediate | 28.2% | Intermediate to Low | 37.3% [27.9–47.4] | 90.6% [79.3–96.9] | 91.0% NPV [80.8–96.0] | 29.4% | |
Intermediate to High | 94.1% [87.6–97.8] | 28.3% [16.8–42.3] | 65.4% PPV [43.8–82.1] | 12.2% | |||
High | 73.6% | High to Very High | 91.2% [76.3–98.1] | 34.0% [25.0–43.8] | 91.5% PPV [77.9–97.0] | 27.3% |